Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Twist Bioscience Trading Up 6.8 %
Shares of NASDAQ TWST opened at $44.47 on Friday. The firm has a market cap of $2.61 billion, a P/E ratio of -11.64 and a beta of 1.77. The business’s 50 day moving average is $43.88 and its 200-day moving average is $43.96. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same period in the prior year, the firm earned ($1.01) EPS. The business’s revenue for the quarter was up 27.7% on a year-over-year basis. Analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current year.
Institutional Investors Weigh In On Twist Bioscience
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. The Goldman Sachs Group increased their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Barclays decreased their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.63.
Check Out Our Latest Analysis on TWST
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Basic Materials Stocks Investing
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.